Factors contributing to failure when treating patients with chronic hepatitis C virus infection

Gastroenterology and Hepatology

Volumn 3, Issue 6 SUPPL. 20, 2007, Pages 4-11

  Shiffman, Mitchell L ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Hepatitis C; Interferon; Re treatment; Treatment failure; Virologic response

Indexed keywords

ANTIRETROVIRUS AGENT; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ALCOHOL CONSUMPTION; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; COMORBIDITY; DEMOGRAPHY; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; ETHNICITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFLUENZA; INSULIN RESISTANCE; LIVER CIRRHOSIS; LIVER FIBROSIS; NEUTROPENIA; OBESITY; PATIENT CARE; PHYSICIAN; RECURRENT DISEASE; RISK FACTOR; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 34447310320     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
3. Hadziyannis SJ, Sette H, Jr, Morgan TR, et al. Peginterferon-a2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
4. Shiffman ML, Suter F, Bacon BR, et al. A randomized controlled trial evaluating 16 and 24 weeks of peginterferon alfa-2a plus ribavirin in patients with HCV genotypes 2 or 3. N Engl J Med. In press.
5. Shiffman ML, Pappas S, Nyberg S, et al. Peginterferon alfa-2A (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 or 3. Final results of the ACCELERATE trial. Presented at the European Association for the Study of Liver 41st Annual Meeting; April 26-30, 2006; Vienna, Austria. Abstract 734.
6. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol. 2005;43:425-433.
7. Shiffman ML. Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders. Curr Gastroenterol Rep. 2006;8:46-52.
8. Shiffman ML. Management of patients with chronic hepatitis C virus infection and previous nonresponse. Rev Gastroenterol Disord. 2004;4(suppl 1):S22-S30.
9. Sethi A, Shiffman ML. Approach to the management of patients with chronic hepatitis C who failed to achieve sustained vitologic response. Infect Dis Clin North Am. 2006;20:115-135.
10. Shiffman ML. Retreatment of patients who do not respond to initial therapy for chronic hepatitis C. Cleve Clin J Med. 2004;71(suppl 3):S13-S16.
11. Shiffman ML. Retreatment of patients with chronic hepatitis C. Hepatology. 2002;36:S128-S134.
12. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology. 2002;36: S114-S120.
13. Sethi A, Shiffman ML. Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response. Clin Liver Dis. 2005;9:453-471,vii-viii.
14. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645-652.
15. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061-1069.
16. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004;126:1015-1023.
17. Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007;132:103-112.
18. Sulkowski MS, Thomas DL. Perspectives on HIV/hepatitis C virus co-infection, illicit drug use and mental illness. AIDS. 2005;19(suppl 3):S8-S12.
19. Thabut D, Le CS, Thibault V, et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol. 2006;101: 1260-1267.
20. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology. 2003;38:639-644.
21. Hughes CA, Shafran SD. Treatment of hepatitis C in HIV-coinfected patients. Ann Pharmacother. 2006;40:479-489.
22. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 2004;39:1702-1708.
23. Romero-Gomez M, Del Mar V, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636-641.
24. Shiffman ML, Hofmann CM, Gabbay J, et al. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. Am J Gastroenterol. 2000;95: 2928-2935.
25. Jacobson IM, Gonzalez SA, Ahmed F, et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol. 2005;100:2453-2462.
26. Marcellin P, Jensen D. Retreatment with Pegasys in patients not responding to prior peginterferon alfa-2b/ribavirin (RBV) combination therapy-efficacy analysis of the 12-week induction period of the REPEAT study. Presented at 56th annual meeting of the American Association for the Study of Liver Diseases; November 11-15, 2005; San Francisco, California. Absrract LB04. Hepatology. 2005;42(suppl 1):749A-750A.
27. Kaiser S, Hass H, Gregor M. Successful retreatment of peginterferon nonresponder patients with chronic hepatitis C with high dose consensus interferon induction therapy. Presented at Digestive Disease Week; May 15-20, 2004; New Otleans, Louisiana. Abstract 125. Gastroenterology. 2004;126(suppl 2): A-668.
28. Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology. 2006;131:1040-1048.
29. Brouwer JT, Nevens F, Bekkering FC, et al. Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. J Hepatol. 2004;40:689-695.
30. Sanchez-Tapias JM, Diago M, Escattin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006;131:451-460.
31. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006;130:1086-1097.
32. Shiffman ML, Price A, Hubbard S, et al. Treatment of chronic hepatitis C virus (HCV) genotype 1 with peginterferon alfa-2b (PEGIFN) high weight based dose ribavirin (RVN) and epoetin alfa (EPO) enhances sustained virologic response (SVR). Presented at the 56th annual meeting of the American Association for the Study of Liver Diseases; November 11-15, 2005; San Francisco, California. Abstract 55. Hepatology. 2005;42 (suppl 1):217A.
33. Anand BS, Currie S, Dieperink E, et al. Alcohol use and treatment of heparitis C virus: results of a national multicenter study. Gastroenterology. 2006; 130:1607-1616.
34. Loguercio C, Di PM, Di Marino MP, et al. Drinking habits of subjects with hepatitis C virus-related chronic liver disease: prevalence and effect on clinical, virological and pathological aspects. Alcohol Alcohol. 2000;35:296-301.
35. Ohnishi K, Matsuo S, Matsutani K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol. 1996;91:1374-1379.
36. Cheung RC, Currie S, Shen H, et al. Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes. Am J Gastroenterol. 2005;100:2186-2193.
37. Sulkowski MS, Thomas DL. Epidemiology and natural history of hepatitis C virus infection in injection drug users: implications for treatment. Clin Infect Dis. 2005;40(suppl 5):S263-S269.
38. Backmund M, Meyer K, Von ZM, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology. 2001;34:188-193.
39. Cournot M, Glibert A, Castel F, et al. Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit. Gastroenterol Clin Biol. 2004;28:533-539.
40. Sylvestre DL, Clements BJ. The impact of negative prognostic factors on hepatitis C treatment outcomes in recovering injection drug user. Presented at the American Association for the Study of Liver Diseases Annual Meeting; November 2-5, 2005; Boston, Massachusetts. Abstract. Hepatology. 2002;36:A223.
41. Krawitt EL, Ashikaga T, Gordon SR, et al. Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. J Hepatol. 2005;43:243-249.
42. Shiffman ML. Side effects of medical therapy for chronic hepatitis C. Ann Hepatol. 2004;3:5-10.
43. Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ ribavirin treatment. Clin Gastroenterol Hepatol. 2006;5:124-129.
44. Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol. 2003;98:2491-2499.
45. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. 2004;126:1302-1311.
46. Pockros PJ, Carithers R, Desmond P, et al. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic heparitis C: a multicenter, randomized controlled trial. Am J Gastroenterol. 2004;99:1298-1305.
47. Collantes RS, Younossi ZM. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. J Clin Gastroenterol. 2005;39(suppl 1):S9-13.
48. Stravitz RT, Chung H, Sterling RK, et al. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. Am J Gastroenterol. 2005;100:1415-1419.
49. Adeyemi OM. Hepatitis C in HIV-positive patients - treatment and liver disease outcomes. J Clin Gastroenterol. 2007;41:75-87.
50. Lai AR, Tashima KT, Taylor LE. Antiretroviral medication considerations for individuals coinfected with HIV and hepatitis C virus. Aids Patient Care STDS. 2006;20:678-692.
51. O'Leary JG, Chung RT. Management of hepatitis C virus coinfection in HIV-infected persons. AIDS Read. 2006;16:313-320.
52. Soriano V, Nunez M, Camino N, et al. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Antivir Ther. 2004;9:505-509.
53. Hoefs J, Aulakh VS. Treatment of chronic HCV infection in special populations. Int J Med Sci. 2006;3:69-74.
54. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.
55. Uka K, Suzuki F, Akuta N, et al. Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection. J Gastroenterol. 2006;41:470-475.
56. Hiramatsu N, Oze T, Kurashige N, et al. Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? Hepatol Res. 2006;35:185-189.
57. Nudo CG, Wong P, Hilzentat N, Deschenes M. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can J Gastroenterol. 2006;20:589-592.
58. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470-477.
59. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites [erratum in N Engl J Med. 2004;351:1268]. N Engl J Med. 2004;350:2265-2271.
60. Shiffman ML, Mihas AA, Mallwala F, et al. Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. Am J Gastroenterol. 2007;102:761-766.
61. Layden-Almer JE, Ribeiro RM, Wiley T, et al. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology. 2003;37:1343-1350.
62. Marrache F, Consigny Y, Ripault MP, et al. Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. J Viral Hepat. 2005;12:421-428.
63. Bruno S, Camma C, Di M, V, et al. Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol. 2004;41:474-481.
64. Lee SS, Bain VG, Peltekian K, et al. Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther. 2006;23:397-408.
65. Everson GT, Hoefs JC, Seeff LB, et al. Impact of disease severity on outcome of antivital therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology. 2006;44:1675-1684.
66. Jacobson IM, Brown R, Freilich B, et al. Response to peginterferon alfa-2b and ribavirin for chronic hepatitis C in patients with body weight >125 kg; results from the WIN-R trial. Presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases; October 27-31, 2006; Boston, Massachusetts. Abstract 369. Hepatology. 2007;44(suppl 1):328A.
67. Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology. 2006;43:1177-1186.
68. Romera M, Corpas R, Romero GM. Insulin resistance as a non-invasive method for the assessment of fibrosis in patients with hepatitis C: a comparative study of biochemical methods. Rev Esp Enferm Dig. 2006;98:161-169.
69. Koike K. Hepatitis C virus infection can present with metabolic disease by inducing insulin resistance. Intervirology. 2006;49:51-57.
70. Zein CO, Levy C, Basu A, Zein NN. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol. 2005;100:48-55.